Ascentage Pharma Group International (AAPG) is a Healthcare · Biotechnology company listed on NASDAQ. Price $15.04 (-2.15%), Market cap $1.82B, 52-week low–high $18.56 ~ $47.90.
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL prote
Financial statements, price targets, institutional (13F) holdings and related news for Ascentage Pharma Group International are updated in real time on BlackAll Trade.
Ascentage Pharma Group International trades at $15.04 (-2.15%). Real-time quotes and charts are available on BlackAll Trade.
Ascentage Pharma Group International has a market cap of about $1.82B.
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's